Filing identity and reporting period
Important mismatch: The supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter and nine months ended March 31, 2013, filed May 14, 2013. It is not a Perspective Therapeutics filing and does not report 2012 Q3. The summary below reflects the filing text provided.
IsoRay develops and sells Cesium-131 brachytherapy products and the GliaSite Radiation Therapy System (RTS). Its principal revenue source remained prostate brachytherapy, with sales also from other treatment applications and GliaSite RTS.
Financial results and position
| Metric | Three months ended Mar. 31, 2013 | Three months ended Mar. 31, 2012 | Nine months ended Mar. 31, 2013 | Nine months ended Mar. 31, 2012 |
|---|---|---|---|---|
| Product sales | $1.251 million | $1.317 million | $3.283 million | $3.759 million |
| Gross profit (margin) | $186,000 (15%) | $204,000 (16%) | $7,000 (less than 1%) | $469,000 (12%) |
| Operating loss | $824,000 | $763,000 | $3.046 million | $2.657 million |
| Net loss | $715,000 | $553,000 | $2.863 million | $2.284 million |
| Loss per share | $0.02 | $0.02 | $0.08 | $0.08 |
| Operating cash used | Not presented separately | Not presented separately | $2.270 million | $1.824 million |
- Cash and cash equivalents were $3.684 million at March 31, 2013, versus $2.673 million at June 30, 2012; restricted cash was $181,000. Cash was approximately $3.54 million on May 1, 2013.
- Current assets were $5.092 million and current liabilities $649,000 at March 31, 2013. The filing reports no conventional borrowings; total liabilities were $1.555 million, including a $775,000 asset retirement obligation and $131,000 warrant derivative liability.
- Nine-month investing cash use was $13,000. Financing provided $3.294 million, primarily from a July 2012 registered stock offering that generated $3.292 million net. Shares outstanding increased to 34.612 million from 30.950 million at June 30, 2012.
Changes versus comparable periods
- Quarterly sales declined 5%; prostate sales fell 10% to $1.006 million, partly offset by a 24% increase in other product sales to $246,000.
- For nine months, sales fell 13%. Prostate sales declined 16% to $2.728 million; other sales rose 7% to $555,000. GliaSite RTS revenue increased approximately $27,000, or 32%, year over year, but remained early-stage.
- Nine-month gross profit fell 99% as lower sales—especially in prostate treatment—were accompanied by largely unchanged cost of sales. Operating loss worsened 15%, and net loss increased 25%.
- Quarterly operating expenses rose to $1.010 million from $967,000. For nine months, operating expenses were $3.053 million versus $3.127 million; lower R&D was partly offset by higher sales and marketing costs and the absence of a prior-year $50,000 R&D reimbursement.
- The reported non-operating gain included a $183,000 nine-month gain from the decrease in the fair value of warrant liabilities (versus $379,000 in the prior-year period). This noncash item reduced reported net loss relative to operating loss.
Outlook, risks, and unusual matters
- Management said May 1 cash of approximately $3.54 million was expected to fund operations and capital expenditures for at least 12 months, assuming revenue and expenses stayed at current levels. The company expected less than $100,000 in capital expenditures during fiscal Q4 and approximately $100,000 of fiscal 2013 protocol expenses.
- Management aimed for breakeven through revenue growth in existing and new applications, GliaSite RTS adoption, and cost control, but gave no quantified revenue or earnings guidance and cautioned that profitability and sales growth were not assured. Management noted prostate sales had continued to decline.
- The company said additional capital might be needed for clinical protocols, sales and production staff, and equipment. Financing could be unavailable or dilutive; management expected future equity financing, if obtained, to be at a discount to market price. The filing warns the company could fall below NYSE MKT minimum stockholders’ equity requirements for the quarter ending June 30, 2013 without additional capital, risking delisting.
- GliaSite uptake was slower than expected, with facility approval and nuclear-materials licensing processes delaying customer adoption. Broader uptake of new treatment applications depended on early adopters and favorable clinical experience and publications.
- A shareholder/licensor disputes whether the company uses licensed know-how subject to a 1% royalty. Prior nonbinding mediation did not resolve the dispute; binding arbitration may be demanded. The company says it does not intend to use the know-how and believes no royalty is due.
- The company carries an asset retirement obligation for radioactive-material removal and leasehold improvements if its production facility is relocated, and identifies product-liability and environmental regulatory risks. It reported no off-balance-sheet arrangements.
- Management judged disclosure controls effective and reported no material change in internal financial-reporting controls during the quarter. Remediation of a material weakness and significant deficiency disclosed in the prior Form 10-K was ongoing, including added accounting personnel and planned training.
Investor verification priorities
- Confirm the filing issuer and period: the supplied document is IsoRay’s March 31, 2013 Form 10-Q, not Perspective Therapeutics’ 2012 Q3 report.
- Assess cash burn against the stated runway, current sales trends, and the assumption that revenue and expenses remain at current levels.
- Verify progress on additional financing and NYSE MKT stockholders’ equity requirements, including potential dilution or delisting.
- Track gross margins and prostate revenue, and evaluate whether growth in other applications and GliaSite RTS can offset declines.
- Review the know-how royalty dispute, asset retirement obligations, and remediation of previously disclosed control deficiencies.